Several reports have suggested that the use of anti-TGF-β monoclonal antibody [12] and TGF-β receptor inhibitor [13] to block the TGF-β pathway could attenuate renal fibrosis in diabetic animal models, but may increase renal inflammation [13]. This evidence concerns the gene TGFB1 and renal fibrosis.